“Psychedelic-assisted therapy” sounds like a single treatment. In research, it is better understood as a treatment package whose drug, psychological support, staffing and schedule can differ substantially between trials.
A typical protocol may include screening, preparation, a monitored administration session and later follow-up or integration. But the amount and type of therapy are not standardised, and the drug’s contribution cannot always be separated from the surrounding care.
ARTICLE AT A GLANCE
01
It is a package
The investigated intervention can include a drug, setting, monitors, preparation and structured follow-up.
02
Protocols differ
Supportive presence, manualised psychotherapy and specific methods such as CBT should not be treated as equivalent.
03
Words affect evidence
To interpret results, readers need to know exactly what both the active and comparison groups received.
In this guide
The common parts of a research protocol
Contemporary trials often start with medical and psychiatric screening, informed consent and preparatory meetings. The administration session then takes place in a controlled environment with trained staff present for monitoring and support. Follow-up sessions may help participants discuss the experience and monitor safety.
The sequence is often summarised as preparation, administration and integration. That summary is useful, but it can hide major differences in session length, therapist training, therapeutic method, number of staff and what happens when distress occurs.
Psychological support is not always psychotherapy
Some studies provide non-directive support intended to maintain safety and reduce distress. Others use a treatment manual with explicit therapeutic aims. Some protocols combine a psychedelic session with an established therapy; others deliberately minimise directive psychotherapy.
A paper should describe the model rather than relying on a broad label. If it does not, the treatment cannot be reproduced easily and readers cannot know which part of the package may have mattered.
What real protocols look like
The registered uAspire psilocybin programme describes preparatory meetings with two facilitators, a supervised administration session lasting several hours and post-session integration. A psilocybin major-depression protocol registered as NCT03866174 similarly includes preparation, a drug or active-placebo session and follow-up.
The MDMA-assisted therapy manual used in MAPS-sponsored research specifies preparatory and integrative sessions around longer drug-assisted sessions delivered by a trained therapy team. That manual was written for approved clinical trials; it is not a general do-it-yourself guide.
Can the drug and therapy effects be separated?
Often, both groups receive some form of psychological support while only the drug assignment changes. That can estimate the difference between drug and control within that support package, but it does not show how the drug would perform without the package.
The FDA’s final psychedelic-trial guidance says the psychotherapy component introduces an additional variable and notes that its contribution to observed efficacy has not been characterised. It suggests designs such as factorial trials when sponsors need to estimate separate contributions.
Why setting is part of the intervention
The acute effects can last for hours and may involve altered perception, emotion and judgement. The physical environment, expectations and behaviour of staff can therefore influence experience, reporting and safety.
That does not mean the setting explains every outcome. It means trial reports should describe it, standardise what can reasonably be standardised and prevent staff knowledge of assignment from changing later therapy.
Questions to ask when reading a study
Who delivered the psychological component, what training and supervision did they receive, was a manual used, how was adherence checked, and were adverse events collected outside the administration day?
Also ask what the comparison group received. “Placebo” may still include hours of staff contact and several therapy sessions, while a wait-list control may receive much less care. Those comparisons answer different questions.
The clearest definition
Psychedelic-assisted therapy is a protocol-defined combination of an investigational drug and surrounding psychological and safety procedures—not one universal therapy.
Safety and scope
Research protocols use screening, trained staff, monitoring and escalation procedures. Their existence should not be used to imply that unsupervised or unregulated use recreates the studied intervention.
ARTICLE RECORD
- Editorial category: Foundational Guides / Evidence & Research
- Evidence status: Multiple protocol models exist; the independent contribution of psychotherapy remains uncertain.
- Sources checked: 29 July 2026
- Independent clinical review: Not independently clinically reviewed.
Sources and further reading
- FDA final guidance: Psychedelic Drugs—Considerations for Clinical Investigations
- ClinicalTrials.gov: uAspire psilocybin study
- ClinicalTrials.gov: Single-dose psilocybin for MDD
- MAPS: MDMA-assisted therapy treatment manual
- MAPP2 protocol and synopsis
Editorial note: This article is for education and evidence literacy. It is not medical advice, a diagnosis, a recommendation to use a substance, or a substitute for care from a qualified professional.
